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Objective: The Endurant (Medtronic, Minneapolis, Minn) is a new stent graft specifically designed to make more patients
anatomically eligible for endovascular aneurysm (EVAR). This study presents the 1-year results of 100 consecutive
patients with abdominal aortic aneurysms (AAAs) treated with the Endurant stent graft in real-life practice.
Methods: All clinical preoperative, operative, postoperative, and 1-year follow-up data of patients with the Endurant stent
graft from three tertiary centers were prospectively collected. Patients underwent computed tomographic angiography
(CTA) preoperatively, at 1 month, and at 1-year post-EVAR. The first 100 patients with an implantation date at least 1 year
before our date of analysis and complete information were included. Clinical data, AAA characteristics, presence of endoleaks,
graft migration, and other EVAR-related complications were noted. All values are stated as mean  SD (range).
Results: This study included 100 patients with AAAs (88 men) with a mean age of 73 8 years (47 to 87 years), an AAA
size of 61  10 mm (31 to 93 mm), an AAA volume of 210  122 mL (69 to 934 mL), a proximal neck length of 33 
14 mm (9 to 82 mm), and an infrarenal angulation of 44  25° (0°-108°). Nineteen of the 100 included patients had at
least one anatomic characteristic that was considered a violation of the instructions for use (IFU) of the Endurant stent
graft. A primary technical success was achieved in 98% of the patients (one additional stent placement in renal artery was
required; one unplanned aorto-uni-iliac device placed), with no primary type I or III endoleaks or conversions. A
secondary technical success was achieved in all cases. The 30-day mortality was 2% and the first postoperative CTA
documented 16 endoleaks (16%; 16 type II). One-year follow-up showed three iliac limb occlusions (3%), one infected
stent graft (causing a type Ia endoleak), and five endovascular reinterventions (5%; three to treat iliac limb occlusions, one
proximal extension cuff; and one stent in the renal artery). The 1-year all-cause mortality rate was 12% (12 patients) and
the AAA-related mortality was 3%. The mean AAA size was significantly smaller after 1 year (diameter, 54 11.8 [32-80]
mm; P< .01; volume, 173 119 [42-1028] mL; P< .01), and one graft migration>5 mm and 13 endoleaks were noted
(12 type II, 1 type I [neck dilatation]).
Conclusion: The treatment of patients with AAAs with the Endurant stent graft seems to be successful and durable during
the first year after EVAR. Despite the wider inclusion criteria for the Endurant, and with 19% of our patients treated
outside the IFU, the AAA-related mortality, number of type I or III endoleaks, and reintervention rates are comparable
to the results of other stent grafts. ( J Vasc Surg 2011;54:609-15.)
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sEndovascular aneurysm repair (EVAR) has evolved to
become an established therapy for patients with abdominal
aortic aneurysms (AAAs) with suitable anatomy since its
introduction in the early 1990s.1 By far, not all patients
with AAAs are, however, considered anatomically suitable
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doi:10.1016/j.jvs.2011.02.053or EVAR and the anatomic inclusion criterion of the
ifferent commercially available stent graft devices are com-
arable.2,3 Especially short or angulated proximal aneu-
ysm necks and tortuous, small or calcified iliac arteries are
elated to adverse EVAR outcomes.4,5 Further technical
mprovements of stent grafts and delivery systems are
eeded to treat these patients safely by EVAR.
The Endurant stent graft (Medtronic, Minneapolis,
inn) is a new stent graft, specifically designed to broaden
he EVAR treatment range. The anatomic inclusion criteria
or the Endurant stent graft, according to its instructions
or use (IFU), are wide compared to other stent grafts.
atients with shorter aneurysm necks and more severe
uprarenal and infrarenal angulations are considered suit-
ble for treatment with the Endurant stent graft (Table I).
The individual stents of the Endurant are designed in a
inusoidal M-shaped form with small amplitude, theoreti-
ally leading to optimal sealing in short and angulated
neurysm necks while possibly making it more forgiving for
izing issues. Small amplitude of stent graft rings is thought
o allow for more flexibility, which may increase the sealing
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September 2011610 van Keulen et alzone in angulated and short necks. Proximal “active fixa-
tion” is provided by a bare stent ring and anchoring pins.
The stent graft has virtually no columnar strength and it is
loaded into the hydrophilic Endurant delivery system with
an outer diameter of 18F to 20F for the main device and
14F to 16F for the limb components.
Preliminary and short-term results in a small number of
patients showed that the Endurant stent graft seems effec-
tive in the treatment of patients with AAAs.6,7 Neverthe-
less, longer-term results of a larger study group in a real-life
practice are mandatory. The purpose of this study was to
investigate the 1-year results of 100 consecutive patients
with AAAs treated with the Endurant stent graft system.
METHODS
All clinical preoperative and peroperative data, as well as
follow-up data of all patients with the Endurant stent graft
of three teaching and tertiary referral hospitals were pro-
spectively collected in a combined database. Patients un-
derwent computed tomographic angiography (CTA) pre-
operatively, within 1month after EVAR, and after 1 year, as
part of a standardized protocol.
Inclusion. The implantation of the Endurant stent
graft started December 2007 in our hospitals. This study
included the first 100 elective patients with AAAs being at
least 1 year after the treatment with a bifurcated Endurant
stent graft system and not being lost to follow-up. Patients
were included on an intention-to-treat basis and patients
that were lost to follow-up were contacted by telephone
but excluded for analysis. Suitability for EVAR treatment
was judged by the treating physicians. The Endurant stent
graft was the stent graft of primary choice for the treatment
of infrarenal AAAs in all participating centers during the
study period.
All available CTA datasets of included patients, being
the preoperative, postoperative, 1-year follow-up, and any
possible additional CTA, were transferred to a 3Surgery 4.0
workstation (3Mensio Medical Imaging BV, Bilthoven,
The Netherlands) for analysis.
Preoperative analysis. The following characteristics
of included patients were obtained preoperatively from our
database: age, gender, American Society of Anesthesiolo-
gists (ASA) score, and laboratory tests for renal function
Table I. Anatomic criteria according to the IFU of the
Endurant stent graft
Proximal aneurysm neck diameter 19-32 mm
Infrarenal neck length 10 mm or 15 mma
Suprarenal neck angulation 45° or 60°a
Infrarenal neck angulation 60° or 75°a
Iliac diameter 8-25
Distal fixation length 15 mm
aAn infrarenal neck is considered suitable for the Endurant stent graft if the
neck length is 10 mm in combination with a suprarenal angulation 45°
and an infrarenal angulation of 60°. If the neck length is 15 mm, then a
suprarenal angulation 60° and an infrarenal angulation of 75° are
accepted.(creatinine). fThe AAA characteristics measured on the preoperative
TA scans were AAA neck length, AAA neck diameter,
alcification and thrombus in the AAA neck, suprarenal and
nfrarenal angulation of the proximal AAA neck, maximum
AA diameter, AAA volume, diameter of the common iliac
rteries, and diameter of the external iliac arteries.
Diameter and length measurements were performed
ith the use of a center lumen line (CLL). All diameters
ere measured from outer-wall to outer-wall. Aortic neck
iameters were measured at the level of the lower border of
he most distal renal artery and every 5 mm from this level
ntil the start of the aneurysm. The calcification and throm-
us in the aortic neck were measured at 10 mm below the
ost distal renal artery and were visually quantified and
lassified into groups of 25%, 25% to 50%, 50% to 75%,
nd75% of the aortic circumference lined by thrombus or
alcification. The aortic suprarenal and infrarenal neck an-
ulations and AAA volumes were measured according to
arlier published protocols.8,9 Diameters of the common
liac arteries were measured 1, 3, and 5 cm distally of the
ortic bifurcation, and the diameters in the external iliac
rteries were measured 1 cm distally of the iliac bifurcation.
The morphology of the proximal aneurysm neck of the
tudy patients was classified as within or outside the IFU of
he Endurant stent graft. Moreover, for comparison, the
roximal aneurysm neck morphology was also classified as
ithin or outside the IFU of the Talent (Medtronic),
enith (Cook, Bloomington, Ind), and the Excluder
Gore, Flagstaff, Ariz) stent grafts.
Perioperative and 1-month postoperative analysis.
he following perioperative characteristics of the study
atients were noted: type of anesthesiology, stent graft size,
ight or left groin used for main device entry, use of stent
raft extensions, operation time, volume of contrast agent
sed, total minutes of fluoroscopy, estimated total blood
oss, endoleaks at completion angiography, complications,
nd procedurally-related problems. Also noted were the
ostoperative hospital length of stay, laboratory tests (cre-
tinine), and the course and possible complications or
einterventions.
The first postoperative CTA scans were evaluated for
he existence of endoleaks, the patency of renal arteries, and
or the distance from the lower border of the most distal
enal artery to the most proximal stent graft ring. The CTA
cans were also checked for any other EVAR-related abnor-
ality, as stent graft kinking, twisting, or infection. All
easurements were performed as on the preoperative
TAs.
One-year postoperative analysis. All complications,
einterventions, outpatient department visits, readmissions,
eaths, causes of death, and extra CTA scans were noted
nd analyzed. The following characteristics were investi-
ated on the CTA performed 1 year after the EVAR pro-
edure: AAA diameter, existence of endoleaks, patency of
enal arteries, diameter of the AAA neck, distance from the
ost distal renal artery to the most proximal stent graft
ing, and AAA volume. The CTA scans were also checked
or any other EVAR-related abnormality. All CTAmeasure-
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Volume 54, Number 3 van Keulen et al 611mentswere performed as on the preoperativeCTAs.Causes of
death in patients that died were investigated by contacting the
treating general practitioner or medical specialist.
Statistics. The perioperative and postoperative out-
comes are reported according to the Reporting Standards
for Endovascular Aortic Aneurysm Repair.10 Data are pre-
sented as mean  SD and range. Statistical analysis of
changes in creatinine, diameter, and volume was performed
by using the t test for paired data. The Kaplan-Meier
method was used to assess cumulative rates of survival,
freedom from secondary interventions, or from type I or
III endoleaks, and freedom from aneurysm-related
death. Statistical significance was assumed at P  .05.
RESULTS
Preoperative results. The first 100 patients with the
Endurant stent graft out of our three centers with an
implantation date at least 1 year before our date of analysis
that were not lost to follow-up were included in this study.
Four patients that were lost to follow-up and did not have
their 1-year follow-up CTA scan were contacted by tele-
phone, and follow-up visits were planned. These patients
were excluded for analysis. All included patients were
treated between December 2007 and March 2009.
The mean age of the 100 included patients (88 men) at
the time of operation was 73 8 years (range, 47-87 years)
and the aneurysm characteristics measured on the preoper-
ative CTAs can be found in Table II. Nineteen of the 100
included patients with AAAs had at least one anatomic
characteristic that was considered a violation of the IFU of
Table II. Preoperative AAA characteristics
Parameter Mean  SD (range)
Maximum diameter, mm 60.6  9.6 (31-93)
Volume, mL 209.9  122 (69-934)
Neck length, mm 33.3  14 (9-82)
Neck diameter, mm 25.5  3.7 (19-34)
Neck calcification, No.
25% 83
25%-50% 13
50%-75% 4
75% 0
Neck thrombus, No.
25% 64
25%-50% 20
50%-75% 8
75% 8
Suprarenal angulation, degree 24  19 (0-96)
Infrarenal angulation, degree 44  25 (0-108)
Right Left
Diameter of the CIA, mm
1 cm 18  7 (10-56) 17  6 (9-44)
3 cm 18  6 (6-44) 17  4 (9-42)
5 cm 18  6 (10-41) 17  4 (9-40)
Diameter of the EIA, mm 10  2 (7-17) 10  2 (5-18)
AAA, Abdominal aortic aneurysm;CIA, common iliac artery; EIA, external
iliac artery.the Endurant stent graft: there were three patients that had 1n aneurysm neck diameter exceeding 32 mm, one patient
ad a suprarenal neck angulation exceeding 60°, and 10
atients had an infrarenal neck angulation exceeding 75°.
oreover, there was one patient that had an aneurysm neck
ength of 9 mm, and one patient had an aneurysm neck
ength of 12 mm along with an infrarenal angulation ex-
eeding 60°. On top of this, there were three patients that
ad more than one anatomic characteristic outside the IFU
f the Endurant; all three patients had a suprarenal neck
ngulation exceeding 60° in combination with an infrarenal
eck angulation exceeding 75°. The suitability of all 100
ncluded patients according to the IFU criteria of other
tent grafts can be found in Table III.
More than 50% of the aortic aneurysm neck lumen was
ined by thrombus or calcification in 20 of the 100 patients.
ive of these 20 patients were also patients with at least one
natomic characteristic that was considered a contraindica-
ion according to the IFU.
The ASA guidelines were preoperatively used to assess
he physical status of all included patients and six patients
ere classified as ASA score I, 45 as ASA score II, 48 as ASA
core III, and one patient as ASA score IV. The mean
reoperative serum creatinine value was 101 45 mol/L
range, 38-413 mol/L; normal reference range, 74-120
mol/L).
Perioperative results. The EVAR procedure was per-
ormed with the patient under general anesthesia in 95 of
he 100 patients and under locoregional anesthesia in five
atients. Themain body of the stent graft was inserted from
he right side in 64 patients, and the deployment of the
tent graft was successful and uncomplicated in 97 patients.
In one patient, however, themain device of a bifurcated
tent graft was placed successfully, but the canalization of
he contralateral limb failed due to severe aortoiliac angu-
ation. To convert this bifurcation graft to an aorto-uni-iliac
evice, an aortic extension was placed in the main device
ver the flow divider, followed by an occluder in the
ontralateral common iliac artery, after which a femoral-
emoral crossover bypass was constructed. In another pa-
ient, the most distal renal artery was unintentionally par-
ially overstented by the main device, which was followed
y successful stent placement in the renal artery during the
ame procedure. In a third patient, an internal iliac artery
as unintentionally overstented. The anatomy of these
hree patients with complicated stent graft deployment was
onsidered suitable for EVAR according to the IFU of the
ndurant stent graft. A primary technical success of the
VAR procedure was achieved in 98% of the procedures
nd a secondary technical success in 100% of the patients.
dditional interventions were performed during the EVAR
rocedures in nine patients; the type of interventions can be
ound in Table IV.
The mean operation time was 102  33 minutes
range, 50-280 minutes), with a mean reported blood loss
f 193  130 mL (range, 10-800 mL), a mean volume of
ontrast agent used of 87  20 mL (range, 35-150 mL),
nd a mean fluoroscopy time of 23  14 minutes (range,
0-80minutes). Completion angiography showed a type II
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September 2011612 van Keulen et alendoleak in 24 patients and no type I or III endoleaks,
conversions to open repair, or procedural deaths were
noted.
One-month postoperative analysis. The mean post-
operative hospital length of stay was 4 5 days (median, 3;
range, 1-45) and there were two endovascular reinterven-
tions within 30 days after the initial operation. In one
patient (treated inside the IFU of the Endurant stent graft),
a covered stent was placed successfully in the renal artery
one day postoperatively because it was suspected on imme-
diate postoperative control CTA that thrombus from the
AAA neck had partly occluded the renal artery during
EVAR. The second patient (treated inside the IFU of the
Endurant stent graft) that underwent reintervention died
within 30 days after EVAR. Ventricular tachycardia devel-
oped one day postoperatively, and an iliac limb was ob-
structed after this low-flow state, which resulted in an
ischemic leg. Endovascular therapy (embolectomy) to solve
this occlusion failed, the patient rejected further treatment
and died 15 days after EVAR.
One other patient (treated inside the IFU of the Endu-
rant stent graft) died during the first 30 days after the initial
procedure. An arterial occlusion developed in this patient’s
lower leg 10 days after EVAR, and heparin therapy was
Table III. IFU anatomic criteria of the Zenith, Excluder,
IFU parameter
Suitability of the 100 in
Zenith n Excluder
Neck diameter 18-28 mm 77 19-29 mm
Neck length 15 mm 96 15 mm
Suprarenal neck angulation 45 88 Not specifie
Infrarenal neck angulation 60 77 60
Total suitable 52
IFU, Instructions for use.
aAn infrarenal neck is considered suitable for the Endurant stent graft if the n
infrarenal angulation of 60°. If the neck length is 15 mm, then a suprar
The suitability of the proximal aneurysm neck of the 100 included patients
Table IV. Additional interventions performed during the
initial EVAR procedure
Additional procedures
No. of
patients
PTA of the common iliac artery 3
Femoral desobstruction 1
Dacron patch plasty to treat femoral artery dissection 1
Bare stent placement in iliac artery and Dacron patch
plasty in femoral artery to treat dissection 1
Interposition graft placement to treat femoral
aneurysm 1
Renal artery stent 1
EVAR, Endovascular aneurysm repair; PTA, percutaneous transluminal
angioplasty.
The renal artery stent and the iliac extension in combination with an
occluder were placed due to complicated stent graft deployment, as stated in
the text.started. The patient suddenly became hemodynamically tnstable 13 days after the operation and died. Autopsy
howed that gastrointestinal bleeding was the cause of
eath.
No other EVAR-related complications were noted dur-
ng the first postoperative month, and 98 control CTAs
ere performed within the first postoperative month. Six-
een endoleaks were seen (16 type II) on these CTAs and
he mean aneurysm neck diameter was 26.4  4.1 mm
range, 19-35 mm). The mean serum creatinine value after
month was 105  50 mol/L (range, 56-273; normal
eference range, 74-120 mol/L, unchanged compared to
he preoperative values [P  .5], mean difference, 3.4
mol/L) and no patients had become dialysis-dependent.
One-year postoperative analysis. Between 30 days
nd 1-year follow-up, three more patients underwent an
ndovascular reintervention. First, a proximal extension
uff was placed successfully in a patient with an infected
tent graft who was considered unfit for open surgery. In
ddition to this, the infected content in the aneurysm sac in
his patient was drained percutaneously. This patient, who
as preoperatively considered eligible for EVAR according
o the IFU of the Endurant stent graft, presented 38 days
fter the initial EVAR procedure with a short history of
ever in combination with abdominal pain. A CTA was
btained, which revealed a type I endoleak, multiple air
ubbles in the aneurysm sac indicating an aneurysm sac
nfection, and a contained AAA rupture. Compared to the
arlier obtained CTA, the AAA had increased 11mm in size
nd the aneurysm neck had disappeared, causing a type I
ndoleak. Second, an embolectomy, followed by placement
f a self-expandable stent in the common iliac artery, was
erformed in a patient with an iliac limb occlusion 3
onths after EVAR. Third, an embolectomy to solve an
liac limb occlusion was performed in another patient after
2 months. In addition to these three endovascular rein-
erventions, one patient developed an inguinal abscess that
equired operative drainage.
Ten patients died between the first 30 postoperative
ays and 1-year follow-up. The earlier-mentioned patient
ith an infected stent graft and aortic cuff placement died
rom sepsis caused by the infected stent graft, despite the
iven therapy. Other causes of death were malignancy in
nt, and Endurant stent graft are given
d patients according to the IFU of different stent grafts
n Talent n Endurant n
86 18-32 mm 97 19-32 mm 97
96 10 mm 99 10 mm or 15 mma 98
 Not specified  45 Or 60a 96
77 60 77 60 Or 75a 86
60 73 81
ngth is10 mm in combination with a suprarenal angulation45° and an
gulation 60° and an infrarenal angulation of 75° are accepted.
ing to these different IFU is shown.Tale
clude
d
eck lewo patients, cardiac disease in two patients, sepsis caused
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eratively existent renal insufficiency in one patient. Two
patients died from unknown causes, although death caused
by a ruptured AAA was considered unlikely since both
patients had an absence of endoleaks on earlier obtained
CTAs.
On the 88 CTAs performed after 1 year, the mean AAA
diameter had decreased significantly to 54.4  11.8 mm
(range, 32-80 mm; P  .01; mean difference 4.9 mm)
and the mean AAA volume had decreased significantly to
174  119 mL (range, 42-1028 mL; P  .01, mean
difference 24.7 mL) when compared to the preoperative
values. The mean aneurysm neck diameter had increased
significantly to 28.3 3.6mm (range, 22-36mm; P .01;
mean difference 2.0 mm) after 1 year when compared to
the direct postoperative aneurysm neck diameter.
The CTAs obtained at 1 year documented 13 patients
with an endoleak (1 type I, 12 type II). The patient with the
type I endoleak was treated inside the IFU of the Endurant
stent graft, and the type I endoleak was very likely caused by
an aneurysm neck dilatation of 4 mm. The placement of a
proximal extension cuff in this patient is planned.
In total, there were five patients with a diameter in-
crease of more than five mm during follow-up (one patient
with a type I endoleak, three patients with a type II en-
doleak, and one patient without endoleak). The patient
with a type I endoleak had a volume increase of 42 mL, and
the patients with a type II endoleak had a volume increase
of 113 mL, 68 mL, and 30 mL, respectively. The patient
without an endoleak had a volume decrease of 42 mL. The
AAA diameter had decreased more than 5 mm during the
first postoperative year in 41 of the 88 patients.
One patient had a stent graft migration of more than 5
mm after 1 year but with enough sealing and fixation length
in the aneurysm neck left. This patient was treated inside
the IFU of the Endurant stent graft.
The serum creatinine value after 1 year had increased
significantly from 101 45 mol/L to 105 34 mol/L
(range, 56-216 mol/L; normal reference range, 74-120
mol/L; P  .01; mean difference 9.9 mol/L). The
estimated freedom from secondary endovascular interven-
tions and type I or III endoleaks after 1 year was 95% (95 of
100) and 98% (98 of 100), respectively (Fig 1). The esti-
mated freedom from aneurysm-related death was 97% (97
of 100). The overall survival after 1 year was 88% (88 of
100; Fig 2).
DISCUSSION
The endovascular repair of AAAs has become an estab-
lished therapy for patients with AAAs with a suitable aneu-
rysm neck anatomy. Many patients are, however, still con-
sidered unsuitable for EVAR due to their anatomy.2,5 One
should be aware that these patients are often also consid-
ered as challenging patients in open surgery.3 These pa-
tients might, therefore, actually benefit most from EVAR.
The introduction of newer stent grafts with wider inclusion
criteria, therefore, could be a step forward in treating these
patients with AAAs. wIn this study, the technical and clinical success rate of
he EVAR procedure with the Endurant stent graft was
igh, and the 1-year secondary intervention rate (5%) was
omparable to the rates of other stent grafts.11 This is
mportant as the inclusion criteria of the Endurant stent
raft are wider compared to those of other stent grafts. On
op of this, even 19% of the patients included in this study
ere treated outside the IFU of the Endurant stent graft.
lthough we are not able to conclude that the Endurant
tent graft makes more patients eligible for EVAR, the
ig 1. Kaplan-Meier curve presents the freedom from secondary
rocedures during the first postoperative year.
Fig 2. Kaplan-Meier curve of the 1-year overall survival.ider inclusion criteria of the Endurant stent graft at least
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patients treated by EVAR.
It has been recently shown that the long-term follow-up
results of EVAR are comparable to those of open aneurysm
exclusion, but the reintervention rate after EVAR was
higher than the reintervention rate after open aneurysm
exclusion.12,13 Therefore, a major challenge is also to de-
crease the reintervention rates after EVAR.12,13 It needs to
be acknowledged that, although decreasing the reinterven-
tion rate after EVAR also is a major goal of new stent grafts,
the reintervention rate in this patient group after 1 year was
comparable to the reintervention rate of other stent
grafts.11,14,15
Three access site-related problems were reported in this
study, and the iliac limb occlusion rate was also 3%, which is
slightly higher than in other stent grafts. In the past, while
using other stent grafts for AAA treatment, we were used to
treating iliac stenosis conservatively if patients were asymp-
tomatic and if the stent graft outflow was symmetric on
completion angiography. Nowadays, after analyzing the
results of the Endurant stent graft, we have decided to treat
all significant stenoses in the aortoiliac area detected on
completion angiography by percutaneous transluminal an-
gioplasty (PTA) to prevent future iliac limb occlusions.
There is, however, no evidence for this preventive therapy
and future results will have to show whether the Endurant
stent graft has more access site and iliac artery-related
problems during follow-up than other stent grafts.
Unintentional coverage of the internal iliac artery dur-
ing stent graft deployment was seen in one patient at
completion angiography. The patency of the internal iliac
arteries in this study was observed preoperatively and at the
completion angiography in all patients. Moreover, there
were, during the 1-year follow-up, no patients that pre-
sented with symptoms of hypogastric artery occlusion.
The aneurysm neck in the 100 patients treated by the
Endurant stent graft dilated from 26.4  4.1 mm (range,
19-35mm) to 28.3 3.6 mm (range, 22-36mm; P .01)
after 1 year. The cause of this neck dilatation is unknown
but might be device-related or due to liberal oversizing of
stent grafts.
The mean volume and diameter of the aneurysm sac of
included patients had decreased significantly during the
1-year follow-up, indicating successful aneurysm exclusion.
The mean diameter shrinkage of AAA sacs during the first
year was more than 6 mm, with a median shrinkage of 4
mm (maximum shrinkage of 18 mm). The aneurysm sac
shrinkage after treatment with the Endurant stent graft is
larger when compared to the AAA shrinkage after the
treatment with other stent grafts.11 The cause of this aneu-
rysm diameter decrease is not known but might indicate a
decreased pressure in the aneurysm sac. A certain amount of
shrinkage of the aneurysm sac in such a short time might,
however, lead to changes in the configuration of the stent
graft in the sac; nevertheless, this did not result in an
impaired clinical outcome.
One of the limitations of this study is that no actual
comparison between the Endurant and any other stent Arafts can be made because the Endurant is the stent graft
f primary choice in the cooperating centers, and no ran-
omized trial was performed. Moreover, the inclusion cri-
eria of the Endurant stent graft are wider than those of
ther stent grafts, thereby making a retrospective compar-
son less reliable. Despite these wider inclusion criteria, up
o 19% of the patients in this series had at least one anatomic
haracteristic considered a violation of the IFU of the
ndurant stent graft. The IFUs of other stent grafts, how-
ver, are stricter and even 27% to 48% of included patients
hat were treated outside the IFU of other stent grafts
Table II). It needs to be said, in light of this, that probably
ot all violations of the IFU are equal, as short necks, for
xample, may be less well tolerated than some neck angu-
ation. Moreover, when comparing the inclusion criteria of
he different stent grafts (Table III), there is a possibility of
election bias. Even though the Endurant stent graft is the
tent graft of primary choice in cooperating centers, pa-
ients included in this study might be treated by the Endu-
ant because they were unsuitable for other devices. Sec-
ndly, there were four patients lost to follow-up that could
ot be included for this study. Although all these patients
ere contacted and were still alive, it cannot be concluded
hat these patients have no EVAR-related complications. It
ight therefore be that these patients lost to follow-up
ight have influenced the outcome of the entire patient
roup, either negatively or positively. Last, there might be
learning curve involved in the use of the Endurant stent
raft. We, as earlier discussed, nowadays preoperatively
reat all significant stenoses in the aortoiliac area detected
n completion angiography. Our centers, however, have
xtensively used the predecessor of the Endurant stent
raft, and we do not believe the learning curve of the use of
he Endurant stent graft will be of much influence on the
esults of this study.
The AAA-related mortality and reintervention rates
uring this first year were acceptable and comparable with
ther studies, although the inclusion criteria for the Endu-
ant are wider.11,16 All reinterventions were performed
ndovascularly, and all but one were successful. The
neurysm-related death rate was 3%, but on the other hand,
he total 1-year related mortality rate of 12% was consider-
ble. An overall survival rate of 88% at 1 year after EVAR is
elatively low, indicating the need for remaining cautious
hile selecting patients for EVAR.
ONCLUSION
This study evaluates the 1-year results of 100 consecu-
ive patients treated with the Endurant stent graft in a
eal-life situation. The treatment of patients with AAAs by
he Endurant stent graft is successful and durable during
he first year after EVAR. The wider inclusion criteria of the
ndurant stent graft do not seem to influence the 1-year
esults negatively.
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